11/22
08:12 am
mnpr
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
Low
Report
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? [Yahoo! Finance]
11/14
07:22 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
11/14
05:16 am
mnpr
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
High
Report
Monopar Therapeutics GAAP EPS of -$0.48 misses by $0.05 [Seeking Alpha]
11/13
08:38 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments [Yahoo! Finance]
11/13
08:00 am
mnpr
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
Medium
Report
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
11/11
07:17 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/25
12:09 pm
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/17
10:26 pm
mnpr
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy [Yahoo! Finance]
Medium
Report
Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy [Yahoo! Finance]
10/15
08:00 am
mnpr
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
Medium
Report
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
10/14
07:59 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
10/13
07:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $125.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $125.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/11
06:14 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Jones Trading from a "hold" rating to a "strong-buy" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Jones Trading from a "hold" rating to a "strong-buy" rating.
10/10
05:21 pm
mnpr
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]
High
Report
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted [Seeking Alpha]
10/6
08:44 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $142.00 price target on by analysts at Raymond James Financial, Inc..
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $142.00 price target on by analysts at Raymond James Financial, Inc..
10/2
10:03 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $115.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $115.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.
9/29
09:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $105.00 price target on by analysts at HC Wainwright.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $105.00 price target on by analysts at HC Wainwright.
9/25
10:17 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
9/25
10:12 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was given a new $95.00 price target on by analysts at Piper Sandler.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was given a new $95.00 price target on by analysts at Piper Sandler.
9/25
08:06 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its price target raised by analysts at BTIG Research from $87.00 to $104.00. They now have a "buy" rating on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its price target raised by analysts at BTIG Research from $87.00 to $104.00. They now have a "buy" rating on the stock.
9/25
08:06 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its price target raised by analysts at Chardan Capital from $60.00 to $85.00. They now have a "buy" rating on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its price target raised by analysts at Chardan Capital from $60.00 to $85.00. They now have a "buy" rating on the stock.
9/25
07:39 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.
9/23
11:17 pm
mnpr
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
9/23
11:17 pm
mnpr
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients [Yahoo! Finance]
Medium
Report
Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients [Yahoo! Finance]
9/23
11:08 pm
mnpr
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
9/23
11:07 pm
mnpr
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
Medium
Report
Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients